VBI Vaccines has completed the acquisition of Epixis, a French company developing virus-like particle (VLP) vaccines on its eVLP platform. The acquisition is complementary to VBI’s suite of thermostable vaccine formulation technologies and enables VBI to develop its own VLP-based vaccines.
VBI Acquires Epixis for VLP Vaccines Capabilities
September 15, 2011 | Media Mentions